abrocitinib oral atopic
Selected indexed studies
- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. (N Engl J Med, 2021) [PMID:33761207]
- Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. (Lancet, 2020) [PMID:32711801]
- Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. (Lancet, 2022) [PMID:35871814]
_Worker-drafted node — pending editorial review._
Connections
abrocitinib oral atopic is a side effect of
Sources
- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. (2021) pubmed
- Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. (2020) pubmed
- Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. (2022) pubmed
- Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. (2020) pubmed
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. (2023) pubmed
- JAK inhibitors in the treatment of atopic dermatitis. (2021) pubmed
- JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review. (2022) pubmed
- Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs. (2024) pubmed
- Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors. (2022) pubmed
- Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure. (2024) pubmed